Diagnostic and treatment challenges of chronic fatigue syndrome: Role of immediate-release methylphenidate – Source: Expert Review of Neurotherapeutics, June 2008
by JR Valdizan Uson and MA Idiazabal AlechaJune 11, 2008
[Methylphenidate (RitalinR) is a prescription central nervous system stimulant commonly used to treat ADHD and daytime drowsiness/narcolepsy. It increases levels of dopamine and norepinephrine in the brain.]
Chronic fatigue syndrome (CFS) is a distinct entity belonging to the group of persistent fatigue that can be challenging to diagnose and to treat. It is characterized by a combination of prolonged fatigue, other nonspecific somatic manifestations and neuropsychological symptoms, including difficulties with concentration, short-term memory and thinking, as well as impaired attention and slowed processing speed.
Neurostimulants increasing dopamine and norepinephrine activity, such as bupropion, dextroamphetamine and recently immediate-release methylphenidate have been advocated to improve neurocognitive deficits.
The use of immediate-release methylphenidate in CFS has been shown in one small study. Using the positive results of this study and the well-known beneficial effects of the drug on a range of similar cognitive symptoms in attention-deficit/hyperactivity disorder, this perspective addresses CFS and other related disorders and provides a discussion on the potential promising role of methylphenidate in the therapeutic armamentarium of CFS.
Source: Expert Review of Neurotherapeutics. June 2008. 8(6):917-27. PMID: 18505357 by Valdizan Uson JR, Idiazabal Alecha MA. Servicio de Neurofisiología Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. [E-mail: jrvaldizan@auna.com]
Copyright © 2009 ProHealth, Inc.
Printed From: http://www.prohealth.com/library/showarticle.cfm?libid=13731